US Merger & Acquisition SEC Filings — July 15, 2026

Completed reverse merger with Lōkahi Therapeutics; Lōkahi securityholders to hold ~90% of combined entity on fully diluted basis, indicating strong insider conviction and a controlling stake. Private placement proceeds will fund legacy CBGM tech as a separate subsidiary.

IPO priced at $10.00/unit, raising $200M (with $30M overallotment option), targeting cash-generative international energy assets. Sponsor affiliation with Samos Investments (special situations energy investor) suggests a focused, high-probability deal pipeline.

Sponsor increased promissory note from $250K to $500K (100% increase), non-interest bearing, convertible at $10.00/unit. This signals sponsor commitment to consummate a deal, with repayment only upon successful business combination.

CEO of HiTech Minerals (Ian Rodger) to participate in a Water Tower Research Fireside Chat on July 16, 2026, to discuss the proposed merger. This forward-looking event may catalyze investor interest, but lack of financial updates keeps sentiment neutral.

Deposited $125K to extend deadline to August 15, 2026. Repeated extensions (monthly) signal difficulty in finding a target, but the sponsor is willing to fund extensions, indicating some commitment.

Deposited only $957.30 for a one-month extension (to August 16, 2026), but remains delisted from Nasdaq since April 2024. Minimal capital committed and no trading venue severely limits deal prospects.

Filed an 8-K with a Fourth Amended and Restated Certificate of Incorporation post-acquisition, limiting director/officer liability. No financial terms disclosed, but the corporate restructuring suggests a completed deal with potential for future value creation.

Preferred stock conversion is subject to stockholder approvals and Nasdaq listing requirements, creating a potential catalyst if approvals are obtained. The reverse merger structure provides a clear path to public listing for Lōkahi.

Suspended from Nasdaq since April 2024, with Form 25 filed in June 2024. The company has no trading venue, making it nearly impossible to raise capital or complete a deal. Extension of only $957.30 suggests minimal sponsor commitment.

Third consecutive monthly extension (now to August 15, 2026) with $125K per month. The SPAC has been unable to announce a target, and the Cayman Islands domicile may limit deal options.

Lōkahi securityholders will hold ~90% of the combined company, severely diluting existing Glucotrack shareholders. The preferred stock conversion is subject to stockholder approvals, creating uncertainty.

The Fireside Chat announcement provides no new financial data or deal progress updates. The merger remains unquantified, and risk factors are extensive.

The $500K note is convertible into units at $10.00, but if the SPAC fails to complete a deal, the sponsor waives claims against the trust. This creates a misalignment if the sponsor pushes for a low-quality deal to avoid losing the note.

Focus on international energy assets exposes the SPAC to commodity price risk, geopolitical instability, and regulatory changes. The 45-day underwriter option adds potential dilution.

The 8-K includes a certificate of incorporation but no purchase price, revenue, or debt details. Investors have no basis to assess the value or quality of the acquisition.

The preferred stock conversion is contingent on Nasdaq listing requirements. If not met, the deal structure may unravel, causing significant downside.

The combined entity will have a publicly listed platform with Lōkahi as the controlling business. The private placement provides capital for legacy CBGM tech, creating a dual-thesis opportunity (biotech + medtech). Trading at low valuation pre-merger.

Priced at $10.00/unit with warrants, offering a low-risk entry point into a SPAC with a clear energy focus. Sponsor's special situations expertise increases likelihood of a value-accretive deal.

The doubling of the promissory note to $500K signals strong sponsor alignment. The conversion price of $10.00/unit provides a floor for post-merger units.

The July 16, 2026 event may provide new details on the merger, including valuation and synergies. If positive, could drive near-term price appreciation.

With shares trading below trust value, the monthly extensions create a potential arbitrage opportunity for investors willing to wait for a deal or liquidation.

The amended certificate of incorporation limits director liability, which may attract quality management. If the undisclosed acquisition is in a high-growth sector, the stock could re-rate.

Given the delisting and minimal extension, the SPAC may be forced to liquidate. If trust value exceeds current market price, there is a potential arbitrage opportunity.

The 45-day underwriter option for up to 3M additional units could increase total IPO proceeds to $230M, providing more firepower for a larger acquisition.

2 of 7 filings (Ribbon, PHP Ventures) are monthly extensions, indicating a struggling SPAC market where many shells are running out of time. PHP's delisting highlights the risk of total loss. Aggregate extension capital is minimal ($125K + $957), suggesting sponsor fatigue.

Samos Energy's IPO and Constellation's HiTech Minerals merger (critical minerals) show a clear tilt toward energy and natural resources. This aligns with broader market trends favoring energy security and critical mineral supply chains.

Glucotrack's reverse merger with Lōkahi Therapeutics demonstrates that private companies are using distressed SPACs or small caps as a backdoor to listing, often with significant dilution for existing shareholders.

Yorkville's doubling of the promissory note and Samos's IPO pricing show that sponsor financial commitment is a critical differentiator. Weak sponsors (PHP) are failing, while well-capitalized sponsors are advancing.

Multiple filings (Constellation, Nuvalent) lack financial terms, making it difficult for investors to assess value. This is a recurring theme in early-stage M&A filings, requiring patience for subsequent disclosures.

Glucotrack's preferred stock conversion is contingent on Nasdaq listing, and PHP's delisting has effectively killed its deal prospects. Exchange listing status is becoming a binary risk factor in SPAC and reverse merger transactions.

July 16, 2026 event may provide merger valuation and timeline updates. Watch for any financial guidance or deal terms.

The preferred stock conversion requires stockholder approval. Monitor proxy filing and vote outcome for potential dilution or deal collapse.

If no deal is announced by August 15, the SPAC may liquidate. Watch for any target announcement or further extension.

With no trading venue, the SPAC is likely to liquidate. Monitor for any last-minute deal or trust distribution announcement.

As a newly IPO'd SPAC, watch for any letter of intent or definitive agreement within the next 12-18 months. Energy sector focus may accelerate deal timeline.

The increased sponsor note suggests a deal is imminent. Monitor for any target leaks or definitive agreement.

The lack of financial terms suggests a more detailed filing is forthcoming. Watch for disclosure of purchase price, revenue, and growth projections.

The preferred stock conversion is contingent on Nasdaq listing. Monitor for any notice of non-compliance or listing approval.